...
首页> 外文期刊>Molecules >Antihyperlipidemic Properties of Novel N-(Benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-Induced Hyperlipidemic Rats
【24h】

Antihyperlipidemic Properties of Novel N-(Benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-Induced Hyperlipidemic Rats

机译:新型N-(苯甲酰基苯基)-5-取代的1H-吲哚-2-羧酰胺在Triton WR-1339诱导的高脂血症大鼠中的抗高脂血症特性

获取原文
           

摘要

In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides (compounds 8-12, 15, 16, 18) and investigating their antihyperlipidemic activity using Triton WR-1339-induced hyperlipidemic rats as an experimental model. Hyperlipidemia was developed by intraperitoneal injection of Triton WR-1339 (250 mg/kg body weight). The tested animals were divided into normal control (NCG), hyperlipidemic (HG), compound 8, 9, 15, 16, 18- and bezafibrate treated groups. At a dose of 15 mg/kg body weight, compounds 9, 16, 18 and bezafibrate (100 mg/kg) significantly (p < 0.0001) reduced elevated plasma triglycerides levels after 12 h compared to the hyperlipidemic control group. However, only the group treated with compounds 9, 16 and 18 showed an obviously significant (p < 0.001) reduction in plasma total cholesterol levels after 12 h compared to the hyperlipidemic control group. Moreover, high density lipoprotein-cholesterol levels were significantly (p < 0.0001) increased in all treated groups after 12 h compared to the hyperlipidemic control group, except for compounds 8 and 15 which revealed inactive. It is therefore reasonable to assume that compounds 9, 16 and 18 may have potential in the treatment of hyperlipidemia.
机译:在寻找新的潜在降血脂药中,本研究着重于合成新型的N-(苯甲酰基苯基)-5-取代的-1H-吲哚-2-羧酰胺(化合物8-12、15、16、18)并对其进行研究。使用Triton WR-1339诱导的高脂血症大鼠作为实验模型来测定抗高脂血症活性。高脂血症是通过腹膜内注射Triton WR-1339(250 mg / kg体重)而产生的。将测试的动物分为正常对照组(NCG),高脂血症(HG),化合物8、9、15、16、18-和苯甲酸酯治疗组。与高脂血症对照组相比,在剂量为15 mg / kg体重的情况下,化合物9、16、18和苯扎贝特(100 mg / kg)在12 h后显着(p <0.0001)降低了血浆甘油三酯升高的水平。但是,与高脂血症对照组相比,只有用化合物9、16和18治疗的组在12 h后血浆总胆固醇水平明显降低(p <0.001)。此外,与高血脂对照组相比,所有治疗组在12 h后高密度脂蛋白胆固醇水平均显着增加(p <0.0001),但化合物8和15表现出无活性。因此,可以合理地假设化合物9、16和18在高脂血症的治疗中可能具有潜力。

著录项

  • 来源
    《Molecules》 |2011年第10期|共13页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 有机化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号